InvestorsHub Logo
icon url

Chiugray

04/01/24 1:03 PM

#682559 RE: XenaLives #682475

XenaLives, Yes. Really critical. Here is where the immune memory derived from DCVax-L is talked about, by Dr. Marnix Bosch ASCO, June 3, 2023. See the Proteomics Analyses - Observations section at 12:19 mark.

So a few of the summary observations are: that the lysate preparations releases multiple cancer-related proteins, from which these peptides can be processed. These dendritic cells pickup, process, and present hundreds of tumor-specific peptides to T cells. Literally hundreds. Imagine now, that you have, that you're a tumor, and you're attacked from a hundred different sites. It's almost impossible to down-regulate those targets, and escape from that immune pressure, which is why we think the product works as well as it does.
It presents peptides from both known GBM-associated tumor antigens, and tumor antigens which have not been reported in GBM before. And the presentation of these peptides, not only through class 1, remember important for cytotoxic T cells, but also through Class 2, to CD4 T cells, suggests that we also get T-cell memory responses in vivo. Something of course, that we believe is incredibly important in a chronic disease like GBM, where you can't just eradicate it at once. You needed ongoing response that continues to hammer away at the tumor. You need to set up that battle in the brain, where the immune system can continue to eradicate tumor cells, because they will continue to replicate otherwise. So this immune memory is actually critical for the, for the potential success. - Dr Marnix Bosch

icon url

Chiugray

04/01/24 2:56 PM

#682602 RE: XenaLives #682475

XenaLives, Also I try to summarize DCVax-L and immune memory fitting in, on a post of mine 676900.
Bullish
Bullish